Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

iwCAR-T 2022

28 Apr–01 May 2022 | Tampa, FL / Online

iwCAR-T 2022

28 Apr–01 May 2022 | Tampa, FL / Online

The 4th International Workshop on CAR-T (iwCAR-T) took place on 28 April – 1 May 2022 in Tampa, FL, with VJHemOnc & VJOncology as official media partners. The workshop is a high-level discussion forum for research leaders in the field of CAR-T to share their perspectives on how to place this evolving understanding in a clinical context and thereby optimize clinical care. This year, a full day was dedicated to CAR-T therapy for solid cancers.

iwCAR-T 2022 has been supported by BMS, Johnson & Johnson, Kite Pharma, Legend Biotech, Instil Bio, Iovance Biotherapeutics, Mustang Bio, A2 Biotherapeutics, Autolus and Chimeric Therapeutics. Supporters have no influence over the production of content.

Emerging CARs and Future Challenges GU Cancers Lung Cancers Breast and ovarian Cancers GI Cancers Head/neck and CNS Cancers Melanoma, Sarcomas
Session I: Emerging CARs and future challenges in solid tumors
Julian Molina
Clinical perspective IO/TILs to BiTEs to TCR to CARs
Julian Molina Mayo Clinic, Rochester, MN, United States
Kim Reiss Binder
anti-HER2 CAR macrophages in solid tumors
Kim Reiss Binder University of Pennsylvania, Philadelphia, PA, United States
Daniel Wang
Human iPSC-derived CAR-Ts with T-cell anti-tumor activity
Daniel Wang City of Hope, Duarte, CA, United States
Session 2: GU cancers
Vivek Narayan
PSMA-redirected Armored CAR-Ts for mCRPC
Vivek Narayan University of Pennsylvania, Philadelphia, PA, United States
Joseph Fraietta
Armored CAR-T therapy in mPC
Joseph Fraietta University of Pennsylvania, Philadelphia, PA, United States
Susan Slovin
P-PSMA-101 CAR-Ts for mCRPC
Susan Slovin Memorial Sloan Kettering Cancer Center, New York City, NY, Afghanistan
David Hong
MAGE-A4 TCR for solid tumors
David Hong The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 3: CAR-T clinical advances in solid tumors – lung
Sandip Patel
Landscape overview
Sandip Patel UC San Diego Health, San Diego, CA, United States
Sylvia Lee
TILs treatment for lung cancer
Sylvia Lee Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Shivani Srivastava
Overcoming barriers to CAR-T therapy in solid tumors
Shivani Srivastava Fred Hutchinson Cancer Research Center, Houston, TX, United States
Melissa Johnson
‘Off-the-shelf’ PRBCs and iNKT cells
Melissa Johnson Sarah Cannon Research Institute, TN, United States
Session 4: Breast and ovarian cancers
Jose Conejo-Garcia
CER T-cell technology for ovarian cancer
Jose Conejo-Garcia H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Winfried Alsdorf
BNT211: CLDN6 CAR-Ts & CARVac-based CAR-T in vivo expansion
Winfried Alsdorf University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Session 5: GI cancers
Joel Randolph Hecht
I-O to cell therapy; IO/T-VEC, BiTEs/TCRs
Joel Randolph Hecht UCLA Health, Los Angeles, CA, United States
Diane Simeone
Precision Promise: an adaptive phase 2/3 platform for drug development
Diane Simeone UC San Diego Health, CA, United States
Mark O'Hara
HuCART-meso cells in patients with pancreatic cancer
Mark O'Hara University of Pennsylvania, Philadelphia, PA, United States
William Go
The future of logic-gated cell therapy
William Go A2 Biotherapeutics, Agoura Hills, CA, United States
Session 6: Head/neck and CNS cancers
Kedar Kirtane
Cellular immunotherapy in head and neck cancers
Kedar Kirtane H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Session 7: Melanoma, sarcomas
Sylvia Lee
TILs for metastatic melanoma
Sylvia Lee Fred Hutchinson Cancer Research Center, Seattle, WA, United States

The 4th International Workshop on CAR-T has been supported by:

The content of VJOncology is intended for healthcare professionals